<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230315057725N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-09-05</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the efficacy of  transverse abdominis plane (TAP) block for  pain  in pediatrics undergoing appendectomy</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the efficacy of ropivacaine in transverse abdominis plane (TAP) block for  pain  in pediatrics undergoing appendectomy : a controlled randomized trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71870</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomization method is used. Candidates in this study were randomly divided into 2 groups in the form of blocks of 4 with equal volume. For this purpose, first 12 blocks of 4 are prepared (Excel software is used to prepare random arrangements inside each block) and then these blocks are arranged randomly and people are assigned to two groups according to A and B are given This action continues continuously until the sample volume is completed. Also, in order to hide the allocation process, closed envelopes will be used, Blinding description: In this study, participants enter the study after obtaining consent and receiving explanations from two study groups. However, the decision about which group they will participate in will be blinded. Additionally, the assessors who evaluate postoperative pain at specified time intervals will be blinded to whether the patient has been enrolled in either of the groups.</study_design>
      <phase>3</phase>
      <hc_freetext>Pain after appendectomy.</hc_freetext>
      <i_freetext>Intervention 1: All patients are first administered intravenous ketamine at a dose of 1.5 milligrams per kilogram in the  waiting room to achieve tranquility before being transferred to the operating room. Subsequently, patients receive sevoflurane 6% along with remifentanil at a dose of 0.6 micrograms per kilogram and rocuronium at a dose of 0.6 milligrams per kilogram intravenously, prior to endotracheal intubation. General anesthesia is maintained with the minimal alveolar concentration of sevoflurane and an infusion of remifentanil at a rate of 0.05 micrograms per kilogram per minute.In the intervention group, tap block is performed using 0.2% ropivacaine at a dose of 0.5 milliliters per kilogram, guided by ultrasound at the end of the surgery and before the patient awakens from general anesthesia. All standard pain management protocols are uniformly applied to both groups postoperatively. Intervention 2: All patients are first administered intravenous ketamine at a dose of 1.5 milligrams per kilogram in the preoperative waiting room to achieve tranquility before being transferred to the operating room. Subsequently, patients receive sevoflurane 6% along with remifentanil at a dose of 0.6 micrograms per kilogram and rocuronium at a dose of 0.6 milligrams per kilogram intravenously, prior to endotracheal intubation. General anesthesia is maintained with the minimal alveolar concentration of sevoflurane and an infusion of remifentanil at a rate of 0.05 micrograms per kilogram per minute.. It's important to note that all standard pain management protocols are uniformly applied to both groups postoperatively.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is It will be done according to the opinion of the research committee of Mashhad University of Medical Sciences.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohadeseh Sabour Darbandi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 63, Daneshjou 14,mashhad,iran</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9188961441</zip>
        <telephone>+98 51 3864 8137</telephone>
        <email>sabourm991@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohadeseh Sabour Darbandi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 63, Daneshjou 14,mashhad,iran</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9188961441</zip>
        <telephone>+98 51 3864 8137</telephone>
        <email>sabourm991@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patient who candidate for appendectomy
Age between 4 to 16 years old
Obtaining informed consent from parents to participate the study</inclusion_criteria>
      <agemin>4 years</agemin>
      <agemax>16 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having other comorbidities
History of previous surgery
Candidate for performing several operations at the same time
Abnormal laboratory data
High body mass index
Perforated appendicitis
Allergic reaction to local anesthetics</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Y48.02</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>local anesthetics</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>All patients are first administered intravenous ketamine at a dose of 1.5 milligrams per kilogram in the  waiting room to achieve tranquility before being transferred to the operating room. Subsequently, patients receive sevoflurane 6% along with remifentanil at a dose of 0.6 micrograms per kilogram and rocuronium at a dose of 0.6 milligrams per kilogram intravenously, prior to endotracheal intubation. General anesthesia is maintained with the minimal alveolar concentration of sevoflurane and an infusion of remifentanil at a rate of 0.05 micrograms per kilogram per minute.In the intervention group, tap block is performed using 0.2% ropivacaine at a dose of 0.5 milliliters per kilogram, guided by ultrasound at the end of the surgery and before the patient awakens from general anesthesia. All standard pain management protocols are uniformly applied to both groups postoperatively.</i_keyword>
      <i_keyword>All patients are first administered intravenous ketamine at a dose of 1.5 milligrams per kilogram in the preoperative waiting room to achieve tranquility before being transferred to the operating room. Subsequently, patients receive sevoflurane 6% along with remifentanil at a dose of 0.6 micrograms per kilogram and rocuronium at a dose of 0.6 milligrams per kilogram intravenously, prior to endotracheal intubation. General anesthesia is maintained with the minimal alveolar concentration of sevoflurane and an infusion of remifentanil at a rate of 0.05 micrograms per kilogram per minute.. It's important to note that all standard pain management protocols are uniformly applied to both groups postoperatively.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain after surgery. Timepoint: Every 4 hours till 12 hours after surgery. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The total amount of analgesics consumption. Timepoint: 12 hours after surgery. Method of measurement: The total dose of morphine consumption.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-04-18</approval_date>
        <contact_name>Faculty of Medicine, Mashhad University of Medical Sciences (Research Ethics Committee)</contact_name>
        <contact_address>No 63, 14 Daneshjou Ave, Daneshjou Boulevar, Mashhadd Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
